Publication: 2304

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 34 (6) 542-549
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
937 is parent abstract
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
5
Parents:
937   2133   2200   2201  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
CA33601, P30 CA016672, 1U10CA180801, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA180801, P50 CA058223, P50-CA58223, U10CA180882, P30 CA008748, U10 CA180791, 1U10CA180838, U10 CA180818, 1U10CA180867, U10 CA180882, U10CA180821, 1U10CA180791, U10 CA180867, U10 CA180838, U10 CA180888, CA31946  
Corr. Author:
 
Authors:
                                     
Networks:
LAPS-CT018, LAPS-MO011, LAPS-NC007, LAPS-NC010, LAPS-NY016, LAPS-UT003, NH038   
Study
CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Rc, Bc6, Bc8, ORIGINAL REPORTS, Rapid Communication